Percutaneous Tricuspid Valve Repair: The Triclip.
Journal
Cardiology in review
ISSN: 1538-4683
Titre abrégé: Cardiol Rev
Pays: United States
ID NLM: 9304686
Informations de publication
Date de publication:
26 Apr 2024
26 Apr 2024
Historique:
medline:
26
4
2024
pubmed:
26
4
2024
entrez:
26
4
2024
Statut:
aheadofprint
Résumé
Tricuspid regurgitation is an often overlooked, but severe cardiac valvular disease associated with significant morbidity and poor quality of life. Tricuspid valve surgery is the only treatment that prevents progression of the disease but is often complicated or made impossible by perioperative risk factors. Due to the high-risk nature, tricuspid valve surgery is typically only done for severe tricuspid regurgitation at the time of left heart surgery, leaving many patients untreated. Medical therapy is limited primarily to diuretic agents, which are often unsuccessful in alleviating symptoms. Treatment of tricuspid regurgitation with transcatheter edge-to-edge repair has emerged after the success of this technique in mitral valve pathologies. This percutaneous procedure parallels surgical principles previously used for valve repair but eliminates the need for cardiac surgery, thus having the potential to serve as an alternative treatment in high-risk patients. The TriClip (Abbott Labs) device is an example of this therapy and the subject of this review.
Identifiants
pubmed: 38666779
doi: 10.1097/CRD.0000000000000685
pii: 00045415-990000000-00240
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
Disclosure: The authors declare no conflict of interest.
Références
Singh JP, Evans JC, Levy D, et al. Prevalence and clinical determinants of mitral, tricuspid, and aortic regurgitation (the Framingham Heart Study). Am J Cardiol. 1999;83:897–902.
Monica T, Gregory N, Janet T, et al. Valvular disease burden in the modern era of percutaneous and surgical interventions: the UK Biobank. Open Heart. 2022;9:e002039.
Topilsky Y, Maltais S, Medina Inojosa J, et al. Burden of tricuspid regurgitation in patients diagnosed in the community setting. JACC Cardiovasc Imaging. 2019;12:433–442.
Possner M, Gensini FJ, Mauchley DC, et al. Ebstein’s anomaly of the tricuspid valve: an overview of pathology and management. Curr Cardiol Rep. 2020;22:157.
Chang JD, Manning WJ, Ebrille E, et al. Tricuspid valve dysfunction following pacemaker or cardioverter-defibrillator implantation. J Am Coll Cardiol. 2017;69:2331–2341.
Condello F, Gitto M, Stefanini GG. Etiology, epidemiology, pathophysiology and management of tricuspid regurgitation: an overview. Rev Cardiovasc Med. 2021;22:1115–1142.
Silbiger JJ. Atrial functional tricuspid regurgitation: an underappreciated cause of secondary tricuspid regurgitation. Echocardiogr. 2019;36:954–957.
Taramasso M, Vanermen H, Maisano F, et al. The growing clinical importance of secondary tricuspid regurgitation. J Am Coll Cardiol. 2012;59:703–710.
Matsuyama K, Matsumoto M, Sugita T, et al. Predictors of residual tricuspid regurgitation after mitral valve surgery. Ann Thorac Surg. 2003;75:1826–1828.
Shiran A, Sagie A. Tricuspid regurgitation in mitral valve disease incidence, prognostic implications, mechanism, and management. J Am Coll Cardiol. 2009;53:401–408.
Généreux P, Pibarot P, Redfors B, et al. Staging classification of aortic stenosis based on the extent of cardiac damage. Eur Heart J. 2017;38:3351–3358.
Izumi C, Iga K, Konishi T. Progression of isolated tricuspid regurgitation late after mitral valve surgery for rheumatic mitral valve disease. J Heart Valve Dis. 2002;11:353–356.
Beckhoff F, Alushi B, Jung C, et al. Tricuspid regurgitation - medical management and evolving interventional concepts. Front Cardiovasc Med. 2018;5:49.
Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA Guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2021;143:e72–e227.
Kurnaz M, Ökçün S, Kahveci G, et al. Cost-effectiveness analysis of the TriClip™ transcatheter tricuspid valve repair system in patients with tricuspid regurgitation. Anatol J Cardiol. 2022;26:198–209.
Belluschi I, Del Forno B, Lapenna E, et al. Surgical techniques for tricuspid valve disease. Front Cardiovasc Med. 2018;5:118.
Kay JH, Maselli-Campagna G, Tsuji KK. Surgical treatment of tricuspid insufficiency. Ann Surg. 1965;162:53–58.
Antunes MJ, Girdwood RW. Tricuspid annuloplasty: a modified technique. Ann Thorac Surg. 1983;35:676–678.
Tang GH, David TE, Singh SK, et al. Tricuspid valve repair with an annuloplasty ring results in improved long-term outcomes. Circulation. 2006;114:I577–I581.
Dreyfus GD, Raja SG, John Chan KM. Tricuspid leaflet augmentation to address severe tethering in functional tricuspid regurgitation. Eur J Cardiothorac Surg. 2008;34:908–910.
Rivera R, Duran E, Ajuria M. Carpentier’s flexible ring versus De Vega’s annuloplasty: a prospective randomized study. J Thorac Cardiovasc Surg. 1985;89:196–203.
Alfieri O, Maisano F. An effective technique to correct anterior mitral leaflet prolapse. J Cardiac Surg. 1999;14:468–470.
De Bonis M, Lapenna E, La Canna G, et al. A novel technique for correction of severe tricuspid valve regurgitation due to complex lesions. Eur J Cardiothorac Surg. 2004;25:760–765.
Lapenna E, De Bonis M, Verzini A, et al. The clover technique for the treatment of complex tricuspid valve insufficiency: midterm clinical and echocardiographic results in 66 patients. Eur J Cardiothorac Surg. 2010;37:1297–1303.
Lee H, Kim J, Oh SS, et al. Long-term clinical and hemodynamic outcomes of edge-to-edge repair for tricuspid regurgitation. Ann Thorac Surg. 2021;112:803–808.
Vahanian A, Beyersdorf F, Praz F, et al.; ESC/EACTS Scientific Document Group. 2021 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J. 2022;43:561–632.
Dreyfus J, Ghalem N, Garbarz E, et al. Timing of referral of patients with severe isolated tricuspid valve regurgitation to surgeons (from a French Nationwide Database). Am J Cardiol. 2018;122:323–326.
Doshi JV, Agrawal S, Garg J, et al. Percutaneous mitral heart valve repair—MitraClip. Cardiol Rev. 2014;22:289–296.
Condado JA, Acquatella H, Rodriguez L, et al. Percutaneous edge-to-edge mitral valve repair: 2-year follow-up in the first human case. Catheter Cardiovasc Interv. 2006;67:323–325.
Mack M, Carroll JD, Thourani V, et al. Transcatheter mitral valve therapy in the United States: a report from the STS-ACC TVT Registry. J Am Coll Cardiol. 2021;78:2326–2353.
Vismara R, Gelpi G, Prabhu S, et al. Transcatheter edge-to-edge treatment of functional tricuspid regurgitation in an ex vivo pulsatile heart model. J Am Coll Cardiol. 2016;68:1024–1033.
Feldman T, Foster E, Glower DD, et al.; EVEREST II Investigators. Percutaneous repair or surgery for mitral regurgitation. N Engl J Med. 2011;364:1395–1406.
Nickenig G, Weber M, Lurz P, et al. Transcatheter edge-to-edge repair for reduction of tricuspid regurgitation: 6-month outcomes of the TRILUMINATE single-arm study. Lancet. 2019;394:2002–2011.
Muntané-Carol G, Alperi A, Faroux L, et al. Transcatheter tricuspid valve intervention: coaptation devices. Front Cardiovasc Med. 2020;7:139.
Sorajja P, Whisenant B, Hamid N, et al.; TRILUMINATE Pivotal Investigators. Transcatheter repair for patients with tricuspid regurgitation. N Engl J Med. 2023;388:1833–1842.
Hausleiter J, Braun D, Orban M, et al. Patient selection, echocardiographic screening and treatment strategies for interventional tricuspid repair using the edge-to-edge repair technique. EuroIntervention. 2018;14:645–653.
Nickenig G, Kowalski M, Hausleiter J, et al. Transcatheter treatment of severe tricuspid regurgitation with the edge-to-edge MitraClip technique. Circulation. 2017;135:1802–1814.
Braun D, Orban M, Orban M, et al. Transcatheter edge-to-edge repair for severe tricuspid regurgitation using the triple-orifice technique versus the bicuspidalization technique. JACC Cardiovasc Interv. 2018;11:1790–1792.
Asmarats L, Puri R, Latib A, et al. Transcatheter tricuspid valve interventions: landscape, challenges, and future directions. J Am Coll Cardiol. 2018;71:2935–2956.
Calabrò P, Gragnano F, Niccoli G, et al. Antithrombotic therapy in patients undergoing transcatheter interventions for structural heart disease. Circulation. 2021;144:1323–1343.
Lurz P, Stephan von Bardeleben R, Weber M, et al.; TRILUMINATE Investigators. Transcatheter edge-to-edge repair for treatment of tricuspid regurgitation. J Am Coll Cardiol. 2021;77:229–239.
Taramasso M, Benfari G, van der Bijl P, et al. Transcatheter versus medical treatment of patients with symptomatic severe tricuspid regurgitation. J Am Coll Cardiol. 2019;74:2998–3008.
von Bardeleben RS, Lurz P, Sorajja P, et al. Two-year outcomes for tricuspid repair with a transcatheter edge-to-edge valve repair from the transatlantic TRILUMINATE trial. Circ Cardiovasc Interv. 2023;16:e012888.
Lurz P, Besler C, Schmitz T, et al. Short-term outcomes of tricuspid edge-to-edge repair in clinical practice. J Am Coll Cardiol. 2023;82:281–291.
Witkowski A, Dudek D, Bartuś S, et al. Innovative medical technologies in the percutaneous treatment of tricuspid regurgitation in Poland. Cardiol J. 2022;29:369–380.
Agricola E, Asmarats L, Maisano F, et al. Imaging for tricuspid valve repair and replacement. JACC Cardiovasc Imaging. 2021;14:61–111.
Besler C, Orban M, Rommel KP, et al. Predictors of procedural and clinical outcomes in patients with symptomatic tricuspid regurgitation undergoing transcatheter edge-to-edge repair. JACC Cardiovasc Interv. 2018;11:1119–1128.
Praz F, Muraru D, Kreidel F, et al. Transcatheter treatment for tricuspid valve disease. EuroIntervention. 2021;17:791–808.
Sorajja P, Chugh Y, Burns M, et al. Simple maneuver to improve TriClip eligibility in patients with cardiac implantable electronic device leads. Circ Cardiovasc Interv. 2023;16:e012950.
Roth E, Noll G, Gämperli O, et al. Percutaneous tricuspid valve repair: a promising treatment for heart transplant patients with severe tricuspid regurgitation. JACC Case Rep. 2021;3:1269–1274.
Afzal S, Haschemi J, Bönner F, et al. Case report: transcatheter edge-to-edge repair after prior surgical tricuspid annuloplasty. Front Cardiovasc Med. 2022;9:1044410.
Barbieri F, Schröder M, Beyhoff N, et al. Percutaneous edge-to-edge tricuspid valve repair in a patient with cor triatriatum dexter: a case report. J Cardiovasc Dev Dis. 2021;8:111–117
Orban M, Besler C, Braun D, et al. Six-month outcome after transcatheter edge-to-edge repair of severe tricuspid regurgitation in patients with heart failure. Eur J Heart Fail. 2018;20:1055–1062.
Pozzoli A, Zuber M, Reisman M, et al. Comparative anatomy of mitral and tricuspid valve: what can the interventionist learn from the surgeon. Front Cardiovasc Med. 2018;5:80.
Russo G, Taramasso M, Pedicino D, et al. Challenges and future perspectives of transcatheter tricuspid valve interventions: adopt old strategies or adapt to new opportunities? Eur J Heart Fail. 2022;24:442–454.
Pedicino D, Vergallo R. Transcatheter repair for severe tricuspid regurgitation: are we going in the right direction? Eur Heart J. 2023;44:2064–2065.
Kodali S, Hahn RT, Eleid MF, et al.; CLASP TR EFS Investigators. Feasibility study of the transcatheter valve repair system for severe tricuspid regurgitation. J Am Coll Cardiol. 2021;77:345–356.
Abdul-Jawad Altisent O, Benetis R, Rumbinaite E, et al. Caval valve implantation (CAVI): an emerging therapy for treating severe tricuspid regurgitation. J Clin Med. 2021;10:4601.
Miller M, Thourani VH, Whisenant B. The Cardioband transcatheter annular reduction system. Ann Cardiothorac Surg. 2018;7:741–747.
Perlman GY, Dvir D. Treatment of tricuspid regurgitation with the FORMA repair system. Front Cardiovasc Med. 2018;5:140.